Zydus Lifesciences Ltd (ZYDUSLIFE) Q4FY26 Management Mirror - Mar-2026 Qtr
Revenue & Segment Growth
In the Mar'26 Qtr, management introduced FY27 guidance, projecting consolidated revenue growth in the high teens. Segment-level FY27 expectations include single-digit growth for the US business (despite base erosion), double-digit momentum for International and Consumer Wellness, and India Formulations outperforming the market by 200 to 400 basis points. Earlier, in the Dec'25 Qtr, the company had projected double-digit growth in India and 20%+ growth in international markets. [Status: Initiated]
4 more themes on the ELITE plan.